Baxter Marks World Hemophilia Day by Reinforcing Commitment to Addressing Disparities in Care and Sharing New Vision for the

  Baxter Marks World Hemophilia Day by Reinforcing Commitment to Addressing
  Disparities in Care and Sharing New Vision for the Future

 Honoring World Federation of Hemophilia 50 Years of ‘Advancing Treatment For

Business Wire

DEERFIELD, Ill. -- April 16, 2013

Baxter International Inc. (NYSE:BAX) today announced its continued commitment
to the hemophilia community to close the gap in hemophilia care and the
company’s vision to pursue a bleed-free world for people living with this
debilitating disorder on World Hemophilia Day.

Approximately 400,000 people worldwide are living with hemophilia,^1 with an
estimated 75 percent remaining undiagnosed and receiving inadequate care or no
care at all.^2 To address these disparities in care, Baxter continues its role
as the founding sponsor of the World Federation of Hemophilia’s (WFH) Global
Alliance for Progress (GAP) program. This healthcare development project, now
in its 11^th year, aims to greatly increase the diagnosis and treatment of
people with hemophilia and other bleeding disorders in developing countries. ^
Since the program’s initiation in 2003, more than 93,000 people in 20
countries have been diagnosed with bleeding disorders (approximately 56,000
with hemophilia).^3 Baxter has donated more than 16 million international
units of product over the past three years through its humanitarian aid
partners, the WFH and AmeriCares to provide factor replacement treatment in
developing countries where it may not otherwise be available.

''Initiatives such as GAP and treatment donation programs are invaluable in
helping the World Federation of Hemophilia improve access to care for people
with hemophilia around the world,'' said Alain Weill, WFH President. ''The
improvement in care has been so remarkable in the past 50 years that patients
in many countries can live their lives without bleeds, and as we look to the
future, we want to ensure all patients have access to the care they need.''

For more than 60 years, Baxter has been a dedicated partner to the hemophilia
community and is committed to helping each patient achieve a life without
bleeds. For people with hemophilia, reducing their bleeding episodes (measured
by annual bleed rate (ABR)) may have a significant improvement on long-term
outcomes and quality of life. Data from a multi-national study conducted by
Baxter showed that children with severe hemophilia A receiving prophylaxis
therapy with zero ABR (n=23/470, 4.9 percent) reported excellent joint
function, no impact on school/work productivity, and health-related quality of
life (HRQoL) similar to a healthy population.^4

To help patients reach this goal, online educational materials and tools are
available at: Each patient can move towards the goal of
living without bleeds working with a healthcare provider to make an
individualized plan to achieve and maintain a low ABR. Personalized approaches
to hemophilia management, including monitoring and tracking ABR, may help
clinicians and patients prevent and reduce bleeding episodes.

''The 50^th anniversary of the WFH is a milestone that signifies remarkable
progress made in the lives of patients living with hemophilia,'' said Brian
Goff, leader of Baxter’s global hemophilia organization. ''Baxter’s vision for
the future is the pursuit of a bleed-free world, one patient at a time,
working with the hemophilia community to help redefine what may be possible
for those living with bleeding disorders.''

About World Hemophilia Day

World Hemophilia Day occurs each year on April 17. Since its creation in 1989,
in honor of the World Federation of Hemophilia’s founder, Frank Schnabel,
World Hemophilia Day has served as an opportunity to increase awareness of
hemophilia and other bleeding disorders and their impact on the global

About Hemophilia A & B

Hemophilia is a rare genetic blood clotting disorder that primarily affects
males.^5 People living with hemophilia do not have enough of, or are missing,
one of the blood clotting proteins naturally found in blood.^5Two of the most
common forms of hemophilia are A and B.^5In people with hemophilia A,
clotting factor VIII is not present in sufficient amounts or is
absent.^5Without enough FVIII, people with hemophilia can experience
spontaneous, uncontrolled internal bleeding that is painful, debilitating,
damaging to joints and potentially fatal.^1,5People with hemophilia B (also
called Christmas disease) do not have sufficient amounts of clotting factor
IX.^5In about 30 percent of cases, there is no family history of hemophilia
and the condition is the result of a spontaneous gene mutation.^6According to
the World Federation of Hemophilia, more than 400,000 people in the world have
hemophilia.^1All races and economic groups are affected equally.^7

About Baxter in Hemophilia

Baxter has more than 60 years experience in hemophilia and has introduced a
number of therapeutic firsts for hemophilia patients. Baxter has the broadest
portfolio of hemophilia treatments in the industry and is able to meet
individual therapy choices, providing a range of options at each treatment
stage. The company’s work is focused on optimizing hemophilia care and
improving the lives of people living with hemophilia A and B worldwide.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures
and markets products that save and sustain the lives of people with
hemophilia, immune disorders, cancer, infectious diseases, kidney disease,
trauma and other chronic and acute medical conditions. As a global,
diversified healthcare company, Baxter applies a unique combination of
expertise in medical devices, pharmaceuticals and biotechnology to create
products that advance patient care worldwide.

^1 World Federation of Hemophilia. Treatment. Accessed April 2013. Available

^2 World Federation of Hemophilia. Close the Gap. Accessed April 2013.
Available at:

^3 Global Alliance for Progress (GAP) 2012 Summary Report and Results.
Prepared by WFH. December 2012.

^4 Haemophilia: Special Issue. Abstracts of the 6th Annual Congress of the
European Association for Haemophilia and Allied Disorders, 6-8 February 2013,
Warsaw, Poland. Volume 19, Issue Supplement s2, PO 033, page 20. Accessed
April 2013. Available at:

^5 About Bleeding Disorders: Frequently Asked Questions. World Federation of
Hemophilia. Accessed April 2013. Available at:

^6 About Bleeding Disorders: How Do You Get Hemophilia? World Federation of
Hemophilia. Accessed April 2013. Available

^7 Center for Disease Control and Prevention. Hemophilia. Accessed April 2013.
Available at:

Photos/Multimedia Gallery Available:



Baxter International Inc.
Media Contacts
Brian Kyhos, (224) 948-4210
Deborah Spak, (224) 948-2349
Investor Contacts
Mary Kay Ladone, (224) 948-3371
Clare Trachtman, (224) 948-3085
Press spacebar to pause and continue. Press esc to stop.